SuperworthEstrella Immunopharma price to book ratio ESLA
Market value divided by the book value of the company's net assets, since 2023.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 200×
- Apr 2025
- Peer median
- 1.9×
Estrella Immunopharma's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.
It was last meaningful in Apr 2025, at 200×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 200× | 44.6× | 200× |
| 2024 | 61.6× | 3.8× | 61.6× |
| 2023 | 3.9× | 3.9× | 5.1× |
Against its peers
Companies in Healthcare nearest Estrella Immunopharma's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| ESLAEstrella Immunopharma | n/m |
| ATNMActinium Pharmaceuticals | 1.6× |
| NEPHNephros | 3.2× |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 1.3× |
| PDEXPro DEX | 4.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| NATRNatures Sunshine Products | 1.3× |
| Peer median | 1.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Estrella Immunopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.